CanSino Biologics to Start China Trial of Inhaled COVID-19 Vaccine

Tianjin CanSino Biologics will start a clinical trial of an inhaled COVID-19 vaccine in China . CanSino worked with the Beijing Institute of Biotechnology to develop the product. Besides the easier delivery method, Xuefeng Yu, chairman and CEO of CanSino suggested it might be effective in infected individuals. Because the virus often enters a body via the airway, anyone already infected would already have a layer of antibody, or T memory cells, which could be quickly activated, he said. More details.... Stock Symbols: (HK: 6185; SHA: 688185) Share this with colleagues: // //